3 recruiting, 2 completed, 2 terminated. 4 Phase 1, 4 Phase 2, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Recruiting 2, Completed 1, Terminated 1 |
| Phase 2 | 4 | Recruiting 2, Completed 1, Terminated 1 |
| Not applicable | 1 | Completed 1 |
Follow this drug Literature Review of Adoptive Transfer trials Research Report on Adoptive Transfer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers E7 TCR-T cells, Aldesleukin - HPV-Associated Cervical Carcinoma, HPV-Related Carcinoma | Phase 1 / Phase 2 | Recruiting | Christian Hinrichs | 15 | 2025-08-11 | 2026-10-06 |
| E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers E7 TCR-T cells, Aldesleukin - Cervical Cancer, Throat Cancer | Phase 2 | Recruiting | Christian Hinrichs | 20 | 2023-03-07 | 2026-06-12 |
| KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer KK-LC-1 TCR-T cells, Aldesleukin - Gastric Cancer, Breast Cancer | Phase 1 | Recruiting | Christian Hinrichs | 30 | 2022-09-26 | 2026-08-25 |
| CD8+ T Cell Therapy and Pembrolizumab in Treating Patients With Metastatic Gastrointestinal Tumors Adoptive Immunotherapy, Aldesleukin, Cyclophosphamide - Colorectal Adenocarcinoma, Metastatic Cholangiocarcinoma | Phase 1 | Terminated | M.D. Anderson Cancer Center | 1 | 2019-08-09 | 2020-10-30 |
| Vemurafenib and TIL Therapy for Metastatic Melanoma Vemurafenib, Lymphodepleting chemotherapy, TIL infusion - Metastatic Melanoma | Phase 1 / Phase 2 | Completed | Inge Marie Svane | 13 | 2014-11-01 | 2020-03-23 |
| Clinical Evaluation of Yervoy in Combination With Adoptive T Cell Transfer for Metastatic Melanoma Patients Adoptive cell transfer, Ipilimumab 5 MG/ML Injection [Yervoy] - A Combination of Adoptive T Cell Therapy and Ipilimumab Could Increase the Proportion of CR Patients, and Durability of Response | Phase 2 | Terminated | Sheba Medical Center | 2 | 2013-10-01 | 2019-04-05 |
| Lymphodepletion Plus Adoptive Cell Transfer With High Dose IL-2 in Patients With Metastatic Melanoma Surgery, Administration of Lymphodepletion, Adoptive Cell Transfer - Metastatic Melanoma | Not applicable | Completed | H. Lee Moffitt Cancer Center and Research Institute | 19 | 2009-10-20 | 2025-12-19 |
Uterine Cervical Neoplasms (3) · Anus Neoplasms (2) · Melanoma (2) · Oropharyngeal Neoplasms (2) · Penile Neoplasms (2) · Stomach Neoplasms (2) · Vaginal Neoplasms (2) · Vulvar Neoplasms (2) · Breast Neoplasms (1) · Cholangiocarcinoma (1) · Colorectal Neoplasms (1) · Esophageal Neoplasms (1) · Lung Neoplasms (1) · Neoplasm Metastasis (1)
Christian Hinrichs (3) · H. Lee Moffitt Cancer Center and Research Institute (1) · Inge Marie Svane (1) · M.D. Anderson Cancer Center (1) · Sheba Medical Center (1)
United States (5) · Denmark (1) · Israel (1)
Christian S Hinrichs, MD (3) · Amod Sarnaik, M.D. (1) · Inge Marie Svane, Prof., MD (1) · Jacob Schachter, Prof. (1) · Michael Overman (1) · Troels Holz Borch, MD (1)
U01CA287904 (1)